Abstract

Onychomycosis is a nail fungal infection, mostly caused by dermatophytes. The treatment efficacy is impaired by difficulties of reaching effective drug levels at the site of infection; frequent relapses occur after cessation of antifungal therapy. The aim of the study was to compare two commercial products containing ciclopirox or efinaconazole for antimycotic activity and antifungal drug resistance. A study of permeation and penetration through bovine hoof membranes, as a nail model, was performed to evaluate the antimycotic activity of permeates against clinical isolates of selected fungi, and the frequency of spontaneous in vitroTrichophyton rubrum-resistant strains was assessed by broth microdilution assays. The results suggest that ciclopirox creates a depot in the nail, leading to a gradual release of the drug over time with action on both the nail plate and bed. Conversely, efinaconazole, mildly interacting with nail keratin, mainly exerts its antifungal activity in the nail bed. However, in the case of T. rubrum, the antifungal activities of the drugs in the nail plate seem comparable. Finally, efinaconazole showed a potential for induction of resistance in T. rubrum, which may limit its efficacy over time. Ciclopirox did not show any potential to induce resistance in T. rubrum and appears endowed with a more complete activity than efinaconazole in the management of onychomycosis as the nail keratin is a substrate for the growth of fungal cells, and the availability of drug in large concentration just in the nail bed may not be sufficient to guarantee the complete eradication of pathogens.

Highlights

  • Onychomycosis is a nail fungal infection, mostly caused by dermatophytes

  • CPX exhibits a broad spectrum of fungicidal activity against a number of medically important fungi and is commercially available in two different formulations based on water-insoluble polymers or on water-soluble hydroxypropyl chitosan (HPCH), the latter of which confers on CPX an improved efficacy in the management of onychomycosis [7]

  • There are some differences in molecular weight and in partition coefficient that influence the affinity toward the hydrophilic ungual substrate: EFI is more lipophilic than CPX

Read more

Summary

Introduction

Onychomycosis is a nail fungal infection, mostly caused by dermatophytes. The treatment efficacy is impaired by difficulties of reaching effective drug levels at the site of infection; frequent relapses occur after cessation of antifungal therapy. The aim of the study was to compare two commercial products containing ciclopirox or efinaconazole for antimycotic activity and antifungal drug resistance. Ciclopirox did not show any potential to induce resistance in T. rubrum and appears endowed with a more complete activity than efinaconazole in the management of onychomycosis as the nail keratin is a substrate for the growth of fungal cells, and the availability of drug in large concentration just in the nail bed may not be sufficient to guarantee the complete eradication of pathogens. The new antifungal agent efinaconazole (EFI), a triazole drug that inhibits fungal lanosterol 14 ␣-demethylase involved in the biosynthesis of ergosterol, has been introduced in the market for the treatment of onychomycosis. EFI displays a broad spectrum of in vitro activity against dermatophytes, nondermatophyte molds, and yeasts, showing a more potent antimicrobial activity than the currently marketed antifungal agents [8,9,10]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call